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Waterborne aripiprazole blunts the 
stress response in zebrafish
Heloísa Helena de Alcantara Barcellos1,2, Fabiana Kalichak1, João Gabriel Santos da Rosa1, 
Thiago Acosta Oliveira1, Gessi Koakoski1, Renan Idalencio1,2, Murilo Sander de Abreu1, 
Ana Cristina Varrone Giacomini2, Michele Fagundes2, Cristiane Variani2, Mainara Rossini2, 
Angelo L Piato3 & Leonardo José Gil Barcellos1,2,4
Here we provide, at least to our knowledge, the first evidence that aripiprazole (APPZ) in the water 
blunts the stress response of exposed fish in a concentration ten times lower than the concentration 
detected in the environment. Although the mechanism of APPZ in the neuroendocrine axis is not yet 
determined, our results highlight that the presence of APPZ residues in the environment may interfere 
with the stress responses in fish. Since an adequate stress response is crucial to restore fish homeostasis 
after stressors, fish with impaired stress response may have trouble to cope with natural and/or 
imposed stressors with consequences to their welfare and survival.
The consumption of antipsychotic drugs has been growing gradually, especially due to the increasing the number 
of diagnostics of psychotic disorders in recent decades1. These drugs induce serious extrapyramidal effects in 
patients who are treated in a continuous and prolonged manner2. In 2002, the US FDA approved the use of arip-
iprazole (APPZ), an atypical antipsychotic with considerably lower occurrence and intensity of adverse effects3,4. 
APPZ has been approved for the treatment of schizophrenia, bipolar mania and major depressive disorder5–9, 
and is useful for controling positive and negative symptoms in schizophrenia10, and irritability, hyperactivity and 
stereotypies in autism11.
Due to its safety and lower incidence of unwanted side effects, the prescription of APPZ is increasing to 
replace classical antipsychotics. This increased use justify the concern about the accumulation of APPZ residues 
in wastewater and, consequently, potential negative effects in non-target organisms such as fish. There are a few 
studies reporting APPZ concentrations detected in effluents12,13, and only one study of cardiovascular risk using 
zebrafish larvae14. In addition, there are no reports on the impact of this drug in adult zebrafish (Danio rerio).
Endocrine disruptors are compounds that alter the normal functioning of the endocrine system of both 
humans and wildlife. We have previously shown that other psychotropic drugs such as risperidone15, fluoxetine, 
diazepam16,17 as well as alcohol18 blunted the response to stress follow acute stress”.
Despite the knowledge on the effects of APPZ in vitro18–20, in rodents21,22 and humans11,23,24, little is known 
about its impact as a possible environmental contaminant. Coupled with the increasing use, interest in the 
study of psychiatry drugs as environmental contaminants13,25,26 and the impact they have on the aquatic fauna 
has risk27–31. Thus, here we describe, for the first time, the effects of different concentrations of APPZ on the 
hypothalamic-pituitary-interrenal (HPI) axis in adult zebrafish.
Results
Two-way ANOVA revealed significant main effects for stress (F1,123 = 10.33, p < 0.0001), as well as a significant 
interaction between the factors (F5,123 = 101.9, p < 0.0001), but not for drug (F5,123 = 1.54; p = 0.1822) (Fig. 1). 
At concentrations of 0.556 and 556 ng/L, APPZ prevented the increase in cortisol levels in stressed zebrafish. 
However, this effect was not observed at other concentrations. On the other hand, APPZ per se did not interfere 
with whole-body cortisol levels. We can also observe that the stressor stimulus was effective.
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Discussion
Here we provide, at least to our knowledge, the first evidence that APPZ in the water decreases the stress response 
of exposed fish. The concentration of 0.556 ng/L, ten times lower than the concentration detected in the envi-
ronment (5.56 ng/L13), blunted the cortisol increase after an acute stressor. This blunting effect of the lower con-
centration, in an environmental perspective, points to the necessity of great caution in relation to the delivery of 
APPZ residues in water bodies.
Interestingly, the HPI-blunting effect was also evident in the higher concentrations of 556 ng/L. This U-shaped 
concentration-response curve suggests a hormetic effect, similar to other psychotropic drugs such as diazepam16 
and risperidone17.
In fact, the mechanism of action of APPZ on the HPI axis of zebrafish is not clear. Our hypothesis is that APPZ 
has a dopaminergic stabilizer effect20, since it is a partial agonist of dopamine receptors30, and tends to buffer 
the effects of endogenous dopamine31. Since dopamine receptors regulate hypothalamic-pituitary-adrenal axis 
activity in rats32, it is possible that APPZ may also act via this mechanism in fish. Our hypothesis based on the 
dopaminergic regulation of HPI axis is reinforced since in unstressed fish, the APPZ did not cause any change 
in cortisol levels, as verified in humans25. In addition, zebrafish treated with a dopaminergic antagonist and sub-
jected to stress did not increase their cortisol, reinforcing the dopaminergic involvement in the HPI activation33.
Despite the undetermined mechanism, our results highlight that the presence of APPZ residues in the envi-
ronment may interfere in the neuroendocrine axis that coordinates the stress responses in fish. In fish, cortisol 
plays a key role in the intermediary metabolism, osmoregulation and immune function34. Thus, the adequate 
stress response is crucial to restoring fish homeostasis after stressors; a fish with an impaired response may have 
trouble to cope with natural and/or imposed stressors with consequences to fish welfare and survival.
A limitation of our study is that we evaluated the effects of acute, but not chronic exposition to AAPZ. Further 
studies are necessary to better understand the effects of chronic exposition of AAPZ on behavioral and neuroen-
docrine parameters in zebrafish.
Furthermore, the zebrafish is a model for translational studies of several human diseases, due to the high 
homology with the human genome35. Although we do not have addressed the mechanism whereby APPZ blocks 
the stress response, this does not lessen the importance of our initial assessment, since, at least to our knowledge, 
this is the first report about an in vivo APPZ effect in fish HPI axis.
Methods
Ethical note. This study was approved at protocol #20/2016, by the Ethics Commission for Animal Use of 
Universidade de Passo Fundo (Passo Fundo, RS, Brazil) and all methods were carried out in accordance with the 
guidelines of National Council of Animal Experimentation Control (CONCEA).
Fish. We used a population of 144 mixed-sex adult wild-type zebrafish (Danio rerio), short-fin strain, and 
50:50 male and female. Fish were acclimatized for 5 days in 3.9 l glass aquaria (20 × 15 × 14 cm), in groups of three 
animals, under constant aeration, with a photoperiod of 14 h light: 10 h dark. Water temperature was maintained 
at 27.4 ± 1.3 °C; pH 6.7 ± 0.3; dissolved oxygen at 5.6 ± 0.5 mg/L; total hardness at 58.9 ± 12.4 mg/L CaCO3, alka-
linity at 45 ± 10 mg/L CaCO3 and ionized ammonia was < 0.011 mg/L.
Study strategy. Our strategy was to expose zebrafish to five concentrations of APPZ and verify the stress 
response of these fish to an additional acute stressor. A possible isolated effect of APPZ was accessed by measur-
ing cortisol in exposed unstressed fish.
Experimental procedures. We distributed fish in 12 groups. Each group consist of four glass aquaria with 
three animals each one (n = 12 per treatment). We then exposed fish to five concentrations of APPZ (Aristab® , 
Aché, Brazil). We set two lower and two higher concentrations (at 10-fold basis) in relation to the APPZ concen-
tration already detected in the environment (5.56 ng/L13). Thus, the five concentrations were 0.0556; 0.556; 5.556; 
55.6 and 556 ng/L.
Figure 1. Whole-body cortisol levels in zebrafish exposed to different concentrations of aripiprazole 
(APPZ, in ng/L) without stressor stimulus (S−) and with stressor stimulus (S+). Each dot represents one 
independent measurement and the black lines represent the mean. Two-way ANOVA followed by Tukey post 
hoc test. n = 9–15 **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. control group (S− ).
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In the exposed and stressed groups, we administered APPZ directly in the water for a 15 min exposure time 
and then we applied the acute stress stimulus by chasing fish with a pen net for 2 minutes. After 15 min the ani-
mals were euthanized for cortisol measurement (see Fig. 1).
After this period, the fish were gently captured and immediately euthanized with cold water, followed by 
decapitation and freeze of the whole body at liquid nitrogen for 30 s. Then, we stored samples at − 20 °C for 
cortisol extraction, following the method described in Oliveira et al.18. The tissue extract was suspended in PBS, 
and whole-body cortisol was measured using a commercially available enzyme-linked immune sorbent (EIAgen 
CORTISOL test, Bio Chem Immuno Systems). This kit is fully validated for zebrafish extracts using the method-
ology described by Sink et al.36.
Statistics. The data is expressed as mean ± standard error of mean (S.E.M). The normal distribution of the 
data was confirmed by Kolmogorov-Smirnov and Levene tests, and results analyzed by two-way ANOVA fol-
lowed by Tukey’s post hoc test. Two-way ANOVA was used to identify the main effects of stress and treatment, as 
well as their interactions. Differences were considered significant at p < 0.05”.
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